[go: up one dir, main page]

PE20020466A1 - Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama - Google Patents

Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama

Info

Publication number
PE20020466A1
PE20020466A1 PE2001000898A PE2001000898A PE20020466A1 PE 20020466 A1 PE20020466 A1 PE 20020466A1 PE 2001000898 A PE2001000898 A PE 2001000898A PE 2001000898 A PE2001000898 A PE 2001000898A PE 20020466 A1 PE20020466 A1 PE 20020466A1
Authority
PE
Peru
Prior art keywords
raloxifene
breast cancer
exemestane
treatment
combination
Prior art date
Application number
PE2001000898A
Other languages
English (en)
Inventor
Clifford A Hudis
Maura N Dickler
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of PE20020466A1 publication Critical patent/PE20020466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE AL USO DE UNA COMBINACION FARMACEUTICA QUE COMPRENDE RALOXIFENO Y EXEMESTANO Y SE ADMINISTRA ENTRE 5 mg/dia A 350 mg/dia DE RALOXIFENO Y ENTRE 5mg A 600mg DE EXEMESTANO. LA COMPOSICION COMPRENDE ALREDEDOR DE 2,4 PARTES EN PESO DE RALOXIFENO Y UNA PARTE EN PESO DE EXEMESTANO UTIL PARA PREVENIR E INHIBIR EL CANCER DE MAMA
PE2001000898A 2000-09-08 2001-09-06 Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama PE20020466A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65767000A 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
PE20020466A1 true PE20020466A1 (es) 2002-06-06

Family

ID=24638159

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000898A PE20020466A1 (es) 2000-09-08 2001-09-06 Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama

Country Status (7)

Country Link
US (1) US20040009962A1 (es)
EP (1) EP1315483A2 (es)
JP (1) JP2004508325A (es)
AR (1) AR034142A1 (es)
AU (1) AU2001287028A1 (es)
PE (1) PE20020466A1 (es)
WO (1) WO2002020000A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
AU2003261233A1 (en) * 2002-07-25 2004-02-16 Massachusetts Institute Of Technology Steroid modulators in the treatment of peripheral nerve sheath tumors
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
WO2016153819A1 (en) 2015-03-25 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis using secondary ion mass spectrometry

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL350291A1 (en) * 1998-12-23 2002-12-02 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Also Published As

Publication number Publication date
WO2002020000A2 (en) 2002-03-14
AU2001287028A1 (en) 2002-03-22
JP2004508325A (ja) 2004-03-18
WO2002020000A3 (en) 2003-02-27
US20040009962A1 (en) 2004-01-15
EP1315483A2 (en) 2003-06-04
AR034142A1 (es) 2004-02-04

Similar Documents

Publication Publication Date Title
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
AR052190A1 (es) Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas
UY34901A (es) ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.
UY27740A1 (es) Nuevos compuestos
BR0107869A (pt) Composições farmacêuticas eletrogiradas
PE20020466A1 (es) Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
SV2002000005A (es) Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
PA8571401A1 (es) Imidazolinilmetil aralquilsulfonamidas
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC Refusal